Merit Financial Group’s Genmab GMAB Stock Holding History

Merit Financial Group’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,526	Closed	-$200K	–	1977
2025 Q3	$200K	Buy	+6,526	New	+$159K	﹤0.01%	1680

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Merit Financial Group's GMAB Position: Q4 2025 in Review

Merit Financial Group sold out of Genmab (GMAB) in Q4 2025, closing a stake of 6,526 shares — an estimated $200K sold.

Merit Financial Group first reported a position in GMAB in Q3 2025 and held it in 1 quarter. The position peaked at $200K in Q3 2025. 293 funds tracked by Wall St. Rank hold GMAB as of Q4 2025.

Merit Financial Group reported no remaining Genmab position as of Q4 2025 after selling out during the quarter.
Merit Financial Group sold 6,526 Genmab shares in Q4 2025, an estimated $200K.
Merit Financial Group first reported a position in Genmab in Q3 2025 and held it in 1 quarter.
Merit Financial Group's Genmab position peaked at $200K in Q3 2025.
293 funds tracked by Wall St. Rank held Genmab as of Q4 2025.

Based on Merit Financial Group's 13F filing for Q4 2025, filed 26 Jan 2026.